Connect with us

Biotech

Exheus Launches into eCommerce and Opens Half a Million Euro Round

This summer, Exheus has received an Enisa loan amounting to $236,000 (€200,000). This is a long-term loan issued by the Ministry and offers extended repayment and grace periods. The interest paid is deductible for corporate income tax purposes and, in the event of a reduction in the company’s capital or liquidation, the loan is treated as book equity. The Exheus tests are based on blood analysis.

Published

on

Exheus goes a step further in the commercialization of its mRNA test. The Spanish startup is preparing the launch of its eCommerce sales service to immediately commercialize its mRNA genetic marker tests. The company expects to earn $355,000 (€300,000) from this sales modality during the remainder of the year.

In June, the company was forced to close the pre-sale period of its genetic tests via eCommerce because it had exhausted its stock. During this process, the company invoiced close to $47,000 (€40,000).

In view of these results, Exheus will launch its online sales service in September. In addition, the start-up, founded in Barcelona as a spin-off of the Institut d’Investigació Sant Pau, is preparing a financing round in autumn valued at half a million euros. The company is currently in talks with several accelerators with which it has already agreed to receive funding. However, the company prefers not to disclose the financial details of these operations.

Read more about the biotech company Exheus and find the latest financial news in the world with our companion app, Born2Invest.

Exheus has received an Enisa loan amounting to $236,000 (€200,000)

This summer, Exheus has received an Enisa loan amounting to $236,000 (€200,000). This is a long-term loan issued by the Ministry and offers extended repayment and grace periods. The interest paid is deductible for corporate income tax purposes and, in the event of a reduction in the company’s capital or liquidation, the loan is treated as book equity.

The Exheus tests are based on blood analysis. These tests are able to sequence mRNA, detect biomarkers and define in a more individualized way how the user’s body functions. With the data collected through these mRNA tests, the company divides its business strategy into two lines. The first (Nutri Diet) is oriented towards nutrition and considers it a main pillar in health prevention, while the second (Exheus Blue Boost) is based on the study of biomarkers focused on sports performance.

SEE ALSO  What you need to know about blood cancer treatments and bone marrow transplants

Exheus is a spin-off of the Institut d’Investigació Sant Pau, the Universitat Politècnica de Catalunya (UPC), and the company Summit

Exheus has its origins as a spin-off of the Institut d’Investigació Sant Pau, the Universitat Politècnica de Catalunya (UPC), and the company Summit and has a staff of twenty employees.

The startup started with an initial investment of $59,000 (€50,000), to which were added another $355,000 (€300,000) from business angels and Acció, the public agency for the competitiveness of Catalan companies, attached to the Department of Enterprise and Labor of the Generalitat de Catalunya.

This entity granted Exheus a direct aid of $88,700 (€75,000). In addition, the Catalan company received $59,000 (€50,000) from mVentures, the startup accelerator of Mobile World Capital Barcelona.

__

(Featured image by geralt via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.

Anthony Donaghue writes about science and technology. Keeping abreast of the latest tech developments in various sectors, he has a keen interest on startups, especially inside and outside of Silicon Valley. From time to time, he also covers agritech and biotech, as well as consumer electronics, IT, AI, and fintech, among others. He has also written about IPOs, cannabis, and investing.

Continue Reading